SPA
EDIT icon

Sherbrooke Park Advisers’s Editas Medicine EDIT Stock Holding History

Sherbrooke Park Advisers’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,024
Closed -$19.1K – 698
2024
Q4 		$19.1K Sell
15,024
-62,639
-81% -$160K 0.01% 717
2024
Q3 		$265K Buy
+77,663
New +$338K 0.06% 627
2024
Q2 		– Sell
-36,858
Closed -$273K – 986
2024
Q1 		$273K Buy
36,858
+24,005
+187% +$199K 0.05% 606
2023
Q4 		$130K Buy
+12,853
New +$113K 0.06% 377

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sherbrooke Park Advisers's EDIT Position: Q1 2025 in Review

Sherbrooke Park Advisers sold out of Editas Medicine (EDIT) in Q1 2025, closing a stake of 15,024 shares — an estimated $19.1K sold.

Sherbrooke Park Advisers first reported a position in EDIT in Q4 2023 and held it in 4 quarters. The position peaked at $273K in Q1 2024. 194 funds tracked by Wall St. Rank hold EDIT as of Q1 2025.

  • Sherbrooke Park Advisers reported no remaining Editas Medicine position as of Q1 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 15,024 Editas Medicine shares in Q1 2025, an estimated $19.1K.
  • Sherbrooke Park Advisers first reported a position in Editas Medicine in Q4 2023 and held it in 4 quarters.
  • Sherbrooke Park Advisers's Editas Medicine position peaked at $273K in Q1 2024.
  • 194 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q1 2025, filed 15 May 2025.